In this review
Compare the full selected program, not every drug at the minimum
MD Exam describes telemedicine visits, nutrition and exercise coaching, and medication from $225 per month. The detailed FAQ separately identifies a $50 consultation fee and says it is refundable if the patient is not approved. The pages do not establish whether that fee is credited toward the selected program. [1] [2]
The actual quote needs to name the drug, branded or compounded preparation, supplied quantity, included care and any testing charge. The homepage discusses compounded options and features semaglutide and tirzepatide experiences, but its minimum is not a complete price table for both drugs. Do not treat it as a universal monthly treatment total.
Put the selected first and ongoing costs into the complete treatment-cost planner.
For another program with distinct introductory and refill prices, compare our MEDVi review.
Insurance acceptance is not a covered-prescription quote
The expanded insurance answer says MD Exam generally accepts major plans and describes checking coverage. The terms make the patient responsible for incurred costs when coverage is absent or denied and expressly decline to guarantee reimbursement. Those statements leave an individual benefits decision to resolve. [1] [4]
Establish separately what the medical visit, selected prescription and any cash alternative will cost. An advertised bundled minimum is not an insured copay, and a familiar medication name does not make a compound eligible for the same coverage as a branded product. The program should remain affordable under the actual answer, not the hoped-for one.
Compare care fees and access models in our provider comparisons.
Clinical contact needs a usable format and schedule
The homepage emphasizes text-based consultations, portal check-ins and progress tracking. The About page also describes a scheduled video visit and access to a nurse. These are useful features, but the selected care arrangement should specify which contact is included and how follow-ups occur. [1] [3]
The terms identify treating providers as independent professionals. They can determine that telehealth is unsuitable, and another provider may cover when the preferred clinician is unavailable. A package does not guarantee the same clinician, immediate responses or a prescription after every request. [4]
Consider the follow-up need alongside the evidence on nausea and clinical follow-up.
The compound needs its own identity and medical reason
MD Exam’s terms say compounded semaglutide and tirzepatide products are not FDA approved and distinguish them from the branded manufacturers’ products. They describe pharmacy choice, with a partner pharmacy used if the patient does not specify one. They do not settle the dispenser or exact formula for every order. [4]
FDA explains that compounds do not receive its premarket safety, effectiveness and quality review, and its GLP-1 guidance reserves compounding for needs an approved drug cannot meet. The actual prescription and pharmacy instructions matter more than a general claim of access without shortages. Ingredient availability does not establish branded-product equivalence or the suitability of compounding for a particular patient. [5] [6]
Keep study products and outcomes distinct with the semaglutide and tirzepatide trial comparison.
The exit cutoff is pharmacy transmission
The FAQ confirms auto-ship. The terms describe a recurring monthly charge until explicit cancellation and require action before medication is sent to the pharmacy to avoid the next charge. Cancellation is described through the patient portal or customer support; no fixed number of advance-notice days is supplied. Confirm the processing event and next bill rather than invent a calendar grace period. [2] [4]
The refund rules distinguish purchases before medical-history review and cases where the patient qualifies for none of the medication-assisted plans, both described as fully refundable. After the patient qualifies and a prescription is written and transmitted, the terms say no refund; medication returns are not accepted. A declined refund can also leave an existing payment plan in place. That is not a satisfaction guarantee after treatment begins. [4]
Plan continuity with the evidence after treatment stops.
Choose for the care you will use, not a results headline
MD Exam publishes a success-rate figure and an average time to lose twenty pounds. Those headline numbers do not explain enough about the study population, comparator and measurement to predict another person’s result. Testimonials also cannot establish that a specific compound reproduces an approved drug’s trial outcomes. [1]
LumiMeds offers another bundled compound comparison, while LifeMD is useful when ongoing clinical care and branded-drug access support are the main reasons to join. MD Exam earns a shortlist place when the actual prescription, contact and total recurring bill are clear, and its coaching adds something the buyer will use.
For another bundled compound service, compare our LumiMeds review.
For branded-prescription access support, read our LifeMD review.
Understanding the cost
Program advertised from $225/month with telemedicine, nutrition/exercise coaching and medication. Detailed FAQ lists a $50 consultation, refundable if not approved. Confirm whether that fee is additional or credited, the chosen drug/preparation, supplied term, testing and the first/recurring total. Insurance claims do not establish a particular covered price. [1] [2] [4]
Build your cost estimateSources
- MD Exam: current weight-care service and actual expanded pricing/insurance answers
- MD Exam: actual expanded program inclusions, state access, $50 consultation and auto-ship answers
- MD Exam: video consultation, coaching and care-access description
- MD Exam: May 26, 2025 terms, independent providers, full operative payment/refund and pharmacy clauses
- FDA: compounded-drug premarket review and quality risks
- FDA: October 1, 2026 concerns with unapproved GLP-1 drugs
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.